Withdrawal of Rimonabant--walking the tightrope of 21st century pharmaceutical regulation?
Taylor
David
D
Pharmacy Department, Maudsley Hospital, and Pharmaceutical Sciences Division, King's College, London, UK. david.taylor@slam.nhs.uk
D019440:Anti-Obesity Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D005060:Europe; D006077:Government Agencies; D006801:Humans; D010880:Piperidines / Q000009:adverse effects* / Q000627:therapeutic use; D011720:Pyrazoles / Q000009:adverse effects* / Q000627:therapeutic use; D000077285:Rimonabant; D018570:Risk Assessment / Q000379:methods
D019440:Anti-Obesity Agents; D010880:Piperidines; D011720:Pyrazoles; D000077285:Rimonabant